Regio- and Stereoselective Synthesis of 3-Pyrazolylidene-2-oxindole Compounds by Nucleophilic Vinylic Substitution of (E)-3-(Nitromethylene)indolin-2-one by Vila Descals, Carlos et al.
 1
 UPDATE 
DOI: 10.1002/adsc.201((will be filled in by the editorial staff)) 
Regio- and Stereoselective Synthesis of 3-Pyrazolylidene-2-
oxindole Compounds by Nucleophilic Vinylic Substitution of 
(E)-3-(Nitromethylene)indolin-2-one. 
Carlos Vila,a* Sophie Slack,a Gonzalo Blay,a M. Carmen Muñozb and José R. Pedroa* 
a Departament de Química Orgànica, Facultat de Química, Universitat de València, Dr. Moliner 50, 46100 Burjassot, 
València (Spain). E-mail: jose.r.pedro@uv.es, carlos.vila@uv.es, 
b Departament de Física Aplicada, Universitat Politècnica de València, Camino de Vera s/n, 46022 València (Spain) 
Received: ((will be filled in by the editorial staff)) 
Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/adsc.201######.((Please 
delete if not appropriate)) 
Abstract. A highly regio- and stereoselective synthesis of 
3-alkylidene-2-oxindoles has been described through a 
nucleophilic vinylic substitution (SNV) of (E)-3-
(nitromethylene)indolin-2-one using pyrazol-3-ones as 
nucleophiles and Et3N as a base. The reaction affords 
selectively the Z-isomer when pyrazol-3-ones without 
substituents at the 4 position are used. While the reaction 
is E-selective with 4-substituted pyrazolones. The 
stereoselectivity (up to >20:1) and the yields (up to 98%) 
are very high under mild reaction conditions. 
Keywords: regioselectivity; pyrazolone; 2-oxindole; 
stereoselectivity; vinylic substitution  
 
Nitrogen-containing aromatic heterocycles are 
omnipresent in agrochemicals, pharmaceuticals and 
natural products.[1] In this context, oxindole scaffold 
represents one of the most important structure for 
medicinal chemistry, due to the large number of 
biologically active compounds that have this scaffold 
in their structure.[2] Therefore, oxindole have become 
in the last decades a privileged skeleton for library 





































Figure 1. Examples of bioactive 3-alkylideneoxindoles 
As an important 2-oxindole structure, unsymmetrical 
3-alkylidene-2-oxindoles[3] are present in various 
natural products[4] and are considered as significant 
pharmacopheres (Figure 1). For example, Tenidap is 
an antirheumatic drug,[5] SU4984[6] and Sunitinib[7] are 
tyrosine kinase inhibitors, and Semaxanib[8] and 
Sunitinib are drugs for the treatment of renal cell 
carcinoma. In view of the great importance of the 3-
alkylidene-2-oxindole skeleton, the regio- and 
stereoselective synthesis of such compounds have 
become an attractive goal for organic synthesis. There 
are several reported synthetic methods to access to 3-
alkylidene-2-oxindoles compounds, such as the aldol 
condensation of 3-unsubstituted oxindoles and  
carbonyl compounds,[9] Wittig reaction of isatins,[10] 
palladium-catalyzed C-H activation-cyclization of N-
aryl-propiolamide,[11] palladium catalyzed cyclization 
reaction of 2-(alkynyl)aryl isocyanates,[12] among 
others.[13] Although these methods are efficient, they 
suffer from some difficulties such as the use of 
hazardous or toxic reagents, generate a lot of waste, 
present poor atom economy or use expensive transition 
metal catalysts. We envisioned that the synthesis of 
unsymmetrical 3-alkylidene-2-oxindoles could be 
achieved by nucleophilic vinylic substitution (SNV)[14] 
of (E)-3-(nitromethylene)indolin-2-one (Scheme 1). 
However, this reaction has been scarcely studied in 
nitroolefins. Moreover, when (E)-3-
(nitromethylene)indolin-2-one is used as an 
electrophile,[15] several challenges have to be 
addressed. First, the regioselectivity[16] of the addition 
step must be controlled since the nucleophile can 
attack the β-position of the nitroolefin (path A) or the 
α-position (path B). Second, in this last path, the 
addition product can progress through a nitrous acid 
elimination reaction whose stereoselectivity must be 
controlled. Xue and Tang, have described the use of 
(E)-3-(nitromethylene)indolin-2-one as an olefination 
reagent for the synthesis  of 3-alkenylindoles using as 
nucleophiles alcohols, thiols and amines with good 
yields and excellents diastereoselectivities to the E 
isomer.[17] They also tried carbon nucleophiles, with 
only one successful example using ethyl 
cyclopentanone-2-carboxylate as nucleophile, 
however with a moderate yield. 
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Scheme 1. Nucleophilic addition of pyrazolones to isatin-
derived nitroalkenes. 
In view of the bibliographic antecedents on the use of 
carbon nucleophiles against (E)-3-
(nitromethylene)indolin-2-one in nucleophilic vinylic 
substitution we decided to test pyrazol-3-ones as 
nucleophiles.  The pyrazolone is a prominent nitrogen 
heterocycle,[18] which is present in numerous 
biologically active compounds with antiinflamatory, 
antiviral, antitumor or antibacterial properties;[19] 
moreover, pyrazol-3-ones are present in several 
pharmaceutical compounds such as edaravone,[20] 
metamizole[21] or remogliflozin etabonate[22]. Given 
the relevance of pyrazol-3-ones and 3-alkylidene-2-
oxindoles, it was anticipated that the incorporation of 
both structural motifs into one molecule could result in 
novel 3-alkylidene-2-oxindoles bearing a pyrazol-3-
one ring with potentially interesting biological 
properties (Scheme 2). As a part of our ongoing 
interest in the nucleophilic addition of pyrazol-3-
ones[23] here we described the highly regio- and 
stereoselective addition of pyrazol-3-ones to (E)-3-
(nitromethylene)indolin-2-ones, providing novel 3-
alkylidene-2-oxindole adducts. The reaction is Z- or E-
stereoselective depending of the substitution pattern at 
the 4 position of the pyrazol-3-one. 
 
Scheme 2. 3-Alkylidene-2-oxindole adducts bearing a 
pyrazol-3-one moiety. 
We initiated our study by using the (E)-1-benzyl-3-
(nitromethylene)indolin-2-one 1a and 5-methyl-2-
phenyl-2,4-dihydro-3H-pyrazol-3-one  (2a) as model 
substrates to study the nucleophilic vinylic substitution 
(SNV) in toluene and in the presence of Et3N (50 
mol%) at room temperature (Table 1). To our delight, 
after 1 hour, 1-benzyl-3-((5-hydroxy-3-methyl-1-
phenyl-1H-pyrazol-4-yl)methylene)indolin-2-one 3aa 
was obtained regioselectively with 59% yield and with 
excellent stereoselectivity to the Z isomer.[24] This is 
remarkable, because in the report of Tang[17] the SNV 
with 1a was stereoselective to the E isomer. We 
attribute the Z stereoselectivity to the presence of a 
hydrogen bonding between the carbonyl of the 
oxindole and the enol form of the pyrazolone. 
Subsequently, a survey of solvents were screened, 
obtaining the best yield (79%) when THF was used as 
a solvent (entry 5, Table 1). Increasing the amount of 
Et3N (entry 6) or using DBU (entry 7) as a base did not 
improved the yield of product 3aa. After the reaction 
was performed at 0 ºC, although the yield of 3aa was 
slightly lower (entry 8). The reaction did not work 
without the presence of a base (entry 9). 
Table 1. Optimization of the reaction conditions.a 
 
Entry Solvent T (ºC) t (h) E:Z (%)b Y. 
(%)c 
1 toluene rt 1 >1:20 59 
2 CH2Cl2 rt 4 >1:20 47 
3 Et2O rt 5 >1:20 62 
4 EtOAc rt 1 >1:20 71 
5 THF rt 1 >1:20 79 
6d THF rt 1 >1:20 72 
7e THF rt 1 >1:20 55 
8 THF 0 ºC 1 >1:20 74 
9f THF rt 30 n.d n.d 
a) Reaction conditions: 0.1 mmol 1a, 0.2 mmol 2a, and Et3N 
(50 mol%) in solvent (2 mL). b) Determined by 1H NMR. c) 
Isolated yield after column chromatography. d) With 100 
mol% Et3N. e) With 50 mol% DBU. f) Without Et3N. 
With the optimized reaction conditions in hand (entry 
5, Table 1), we proceeded to study the scope of the 
nucleophilic vinylic substitution of 1 with different 
pyrazol-3-ones 2 (Scheme 3), obtaining excellent 
regio- and stereoselectivities to the Z isomer (>20:1), 
and moderate to good yields (57-81%). First we tested 
different nitroalkenes derived from isatines with 
pyrazol-3-one 2a. Initially, N-substitution of the 
oxindole nitrogen was evaluated (Scheme 1, 3aa-3fa). 
Groups such as benzyl, methyl, allyl, propargyl or –
CH2CO2Me were well accommodated, obtaining the 
corresponding adducts with good yields (65-79%). In 
 3
addition, non-protected free NH on the oxindole ring 
was also tolerated (3fa), which allows easy potential 
N-substitutions on demand. Electron-donating (MeO, 
Me) or electron-withdrawing (Cl or Br), were tolerated 
at the 5, 6 or 7 positions of the isatin-derived 
nitroalkene, affording the corresponding products 
(3ga-3ka) with excellent regio- and stereoselectivity 
and good yields (57-77% yield). Different pyrazol-3-
ones 2 were also evaluated in the reaction with 
nitroalkene 1a. So, 2,5-dimethyl-pyrazol-3-one 2b 
was tested with nitroalkene 1a and 1b, leading to the 
corresponding products 3ab and 3bb, with lower 
yields than product 3aa. Nevertheless, the reaction 
proceeded efficiently with pyrazolones with diverse 
substituents (MeO or Cl) in the N-aryl group (3ad-3ae). 
Moreover, when 2,5-diaryl-pyrazol-3-ones were tested 
the corresponding product 3ac, 3af and 3ag were 
afforded with good yields (65-71%). The 
configuration of the double bond in product 3ka, was 


























































































































































































Scheme 3. Substrate scope of the SNV reaction. Reaction 
conditions: 0.1 mmol 1, 0.2 mmol 2, and Et3N (50 mol%) in 
THF (2 mL) at rt. 
After having proved the efficiency of our methodology 
for the SNV reaction of isatin-derived nitroalkenes 
with pirazolones 2, we decided to study the reaction of 
1a with pyrazol-3-ones bearing a substituent at 4 
position. Our initial studies were focused on the 
addition of 4,5-dimethyl-2-phenyl-2,4-dihydro-3H-
pyrazol-3-one (4a) to nitroalkene 1a (Table 2). First, 
we evaluated the reaction in the initial conditions used 
in Table 1 (50 mol% Et3N in toluene as a solvent). The 
corresponding 3-alkylidene-2-oxindole 5aa bearing a 
pyrazolone moiety was obtained with 70% yield and a 
good 10:1 E:Z ratio after 4 hours reaction time (entry 
1, Table2). In this SNV reaction, the favoured product 
is the E product. At this point, we decided to use 1 eq. 
of Et3N as a base (entry 2), obtaining the product 5aa 
with an improvement of the yield (98%) although with 
a slight decrease in stereoselectivity (9:1 E:Z ratio) 
after 0.5 hour of reaction time (entry 2, Table2). 
Different solvents such as THF, CH2Cl2, CHCl3, Et2O 
or EtOAc were tested using 1 eq. of Et3N. The best E:Z 
ratio (>20:1) in product 5aa, was obtained when 
CHCl3 was used as a solvent (entry 5), without 
compromising the yield (96%).  
Table 1. Optimization of the reaction conditions.a 
 
Entry Solvent t (h) E:Z (%)b Yield (%)c 
1d toluene 4 10:1 70 
2 toluene 0.5 9:1 98 
3 THF 1 2:1 98 
4 CH2Cl2 1 13:1 94 
5 CHCl3 1 >20:1 96 
6 Et2O 1 12:1 93 
7 EtOAc 1 6:1 78 
a) Reaction conditions: 0.1 mmol 1a, 0.2 mmol 4a, and Et3N 
(100 mol%) in solvent (2 mL) at rt. b) Determined by 1H 
NMR. c) Isolated yield after column chromatography. d) 
With 50 mol% of Et3N. 
Having established the optimal reaction conditions 
(entry 5, Table 1), the scope of the SNV reaction using 
several 4-substituted-pyrazol-3-ones was evaluated 
(Scheme 4). First, in the case of 4-substituted-
pyrazolones, the N-substitution of oxindole was 
investigated (Scheme 4, 5aa-5fa). Groups such as 
benzyl, methyl, allyl, propargyl or CH2CO2Me were 
well tolerated, and the corresponding products 5 were 
obtained with excellent yields (76-96% yield) and 
excellent E:Z ratio, although the unprotected 5fa was 
gained with lower yield (67%). Next, the effect of 
substitution in the benzene ring of the N-benzyl 
protected isatin-derived nitroalkenes was studied (1g-
1k). Different electron-donating (Me or MeO) or 
electron-withdrawing (Cl or Br), were tolerated at 
different positions of the isatin-derived nitroalkenes, 
 4
affording the corresponding products 5 with good 
yields (62-87% yield) and excellent E stereoselectivity. 
Next, the substrate scope with respect to other 4-
substituted pyrazol-3-ones 4 was evaluated (5ab-5af) 
obtaining excellent values of E:Z ratios, with high 
yields (69-95%). The configuration of the double bond 






















































































































































5af, 20:1 dr, 95% yield
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Scheme 4. Substrate scope of the SNV reaction. Reaction 
conditions: 0.1 mmol 1, 0.2 mmol 4, and Et3N (100 mol%) 
in CHCl3 (2 mL) at rt. 
On the basis of the experimental results, we propose a 
plausible mechanism for the regio- and stereoselective 
SNV reaction as is depicted in the Scheme 5. By the 
action of a base, the intermediate 6 is generated after 
the regioselective nucleophilic addition of the pyrazol-
3-one to the α-position of nitroalkene 1. We believe 
that the addition of the pyrazol-3-one, occurs at this 
carbon due to the steric effects. When the pyrazolone 
does not have substituents at 4 position, intermediate 6 
switches to the intermediate 7, favored by an 
intramolecular hydrogen bond between the carbonyl of 
the oxindole and the enol form of the pyrazolone 
moiety (intermediate 7). The hydrogen bond prompts 
a fast 1,2-trans-elimination in the presence of a base to 
afford the Z-3-alkenyl-2-oxindole 3aa. However, 
when the pyrazolone have a substituent at 4-position, 
the intermediate 6 switches to an eclipsed 
conformation, (intermediate 8), which is favored by an 
intramolecular hydrogen bond between the nitro group 
and the hydrogen of the C-3 of oxindole through a 
five-membered ring.[17] In this case, in the presence of 
a base, the hydrogen bond prompts a fast 1,2-cis-
elimination to afford the E-3-alkenyl-2-oxindole 5aa. 
The base, in this SNV reaction, assists the 
regioselective nucleophilic addition, as well as the 
stereoselective elimination.  
 
Scheme 5. Plausible mechanism for the SNV reaction. 
In conclusion, we have developed a nucleophilic 
vinylic substitution of pyrazol-3-ones to isatin- 
derived nitroalkenes, using Et3N as a base, obtaining 
stereoselectively 3-alkenyl-2-oxindole bearing a 
pyrazolone moiety. The stereoselectivity towards the 
E or Z double bond formation depends of the 
substitution pattern of the pyrazol-3-one at 4 position. 
If the pyrazolone does not have a substituent at 4 
position, the corresponding products 3, are obtained 
with good yields (up to 81%) and >1:20 E:Z ratio. 
While, with 4-substituted pyrazol-3-ones the reaction 
affords 3-alkenyl-2-oxindoles adducts 5 with excellent 
yields (up to 96%) and up to >20:1 E:Z ratio. The 
present methodology represents a powerful synthetic 
tool for the stereoselective synthesis of potentially 
bioactive 3-alkenyl-2-oxindole adducts bearing a 
pyrazolone moiety. 
Experimental Section 
General procedure for the SNV reaction with 
nitroalkenes 1 and pyrazolones 2. 
In a 10 mL round bottom flask, 3-nitromethylene-2-
indolinone 1 (0.1 mmol) and pyrazol-3-one 2 (0.2 mmol) 
were dissolved in THF (2 mL). Triethylamine (50 mol%, 
0.05 mmol, 7 µL) was added. The mixture was stirred at 
room temperature until completion (TLC). The THF was 
removed under reduced pressure and the residue was 
purified by column chromatography being eluted with 
hexane/EtOAc 98:2 to hexane/EtOAc 95:5, affording 
product 3. 
 5
General procedure for the SNV reaction with 
nitroalkenes 1 and pyrazolones 4. 
In a 10 mL round bottom flask, 3-nitromethylene-2-
indolinone 1 (0.1 mmol) and 4-substituted pyrazol-3-one 4 
(0.2 mmol) were dissolved in CHCl3 (2 mL). Triethylamine 
(100 mol%, 0.1 mmol, 15 µL) was added. The mixture was 
stirred at room temperature until completion (TLC). Finally, 
the reaction mixture was directly poured into a column for 
chromatography, and the crude product was purified using 
hexane/EtOAc 95:5 or DCM/EtOAc 100:0 to 95:5, 
affording product 5. 
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